Furthermore, the national health insurance system in Taiwan covers a GLP-1 receptor agonist prescription only when patients have known cardiovascular disease, cerebrovascular disease, or poor glucose control despite other treatment. Here, GLP1R is linked to cerebrovascular disorder.